Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer’s disease: an updated meta-analysis

@article{Wang2009EfficacyAS,
  title={Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer’s disease: an updated meta-analysis},
  author={Bai-song Wang and Hao Wang and Zhaoxu Wei and Yan-yan Song and Lu Zhang and Hong-Zhuan Chen},
  journal={Journal of Neural Transmission},
  year={2009},
  volume={116},
  pages={457-465}
}
The objective of this study was to provide an updated meta-analysis of the efficacy and safety of huperzine A (HupA) in Alzheimer’s disease (AD). [] Key Method We searched for randomized trials comparing HupA with placebo in the treatment of AD. The primary outcome measures were mini-mental state examination (MMSE) and activities of daily living scale (ADL). Data were extracted from four randomized clinical trials and analyzed using standard meta-analysis and meta-regression methods. Oral administration of…
The Efficacy and Safety of Alzheimer’s Disease Therapies: An Updated Umbrella Review
TLDR
This study demonstrated that AChE inhibitors, Ginkgo biloba, and cerebrolysin are the optimum cognitive and activities of daily living medication for patients with AD.
Treatment with Huperzine A Improves Cognition in Vascular Dementia Patients
TLDR
Hperzine A can significantly improve the cognitive function in patients with mild to moderate vascular dementia, and the medicament is safe.
Identification of the optimal cognitive drugs among Alzheimer’s disease: a Bayesian meta-analytic review
TLDR
As the first NMA comparing the major drugs in market for AD, this study suggests that memantine might have a more significant benefit on cognition than other five drugs available.
Anti-Acetylcholinesterase Derivatives: A Privileged Structural Framework in Drug Discovery to Treat Alzheimer’s Disease
TLDR
There is a need for the discovery of more effective compounds derived from natural sources as well as form synthetic sources as potential AChEIs.
The effects of Huperzine A on dementia and mild cognitive impairment: An overview of systematic reviews
TLDR
There is insufficient evidence to support the effectiveness of Hup A in cognitive impairments due to the high heterogeneity of SRs and the low quality of primary studies, so high-quality, large multicenter RCTs with long-term follow-up in different settings are warranted.
New insights into huperzine A for the treatment of Alzheimer's disease
TLDR
The present article is made to discuss the current progress and future perspective for huperzine A therapy in AD.
The Role of Phytochemicals in the Treatment and Prevention of Dementia
TLDR
The potential and actual therapeutic strategies for dementia in relation to the known mechanisms of dementia pathology are presented and plant extracts that have shown relevant mechanistic effects for dementia and promising clinical data, but require more evidence for their clinical efficacy and safety are presented.
...
...

References

SHOWING 1-10 OF 43 REFERENCES
[Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial].
TLDR
A safe and effective medicine, huperzine Alpha remarkably improves the cognition, behavior, ADL,and mood of AD patients.
Evaluation of clinical effect and safety of huperzine A in treating 52 Alzheimer's disease
TLDR
Huperzine A is effective in treating ADients with slight adverse reaction, and shows much higher rates of improvement in terms of cognitive function and daily living with clinical global impression than those of the control group at 24wk after treatment.
Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease.
  • S. Xu, Z. X. Gao, X. Chai
  • Medicine, Psychology
    Zhongguo yao li xue bao = Acta pharmacologica Sinica
  • 1995
TLDR
Hup is a promising drug for symptomatic treatment of Alzheimer's disease and was better than placebo in patients treated with Hup, with improvements in memory, cognitive, and behavioral functions.
Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease.
TLDR
A comprehensive survey of the progress in chemical and pharmacological studies of H upA including the isolation and structure elucidation, pharmacological actions, total synthesis, SAR studies and the future development of HupA is dealt with.
An update on huperzine A as a treatment for Alzheimer's disease
TLDR
The development of huperzine A as a treatment for AD is reviewed, including the Phase II trial now under way in the US, which may compare favorably in symptomatic efficacy to cholinesterases in use.
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
TLDR
The data indicate that donepezil is a well-tolerated drug that improves cognition and global function in patients with mild to moderate AD.
Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
TLDR
The use ofdonepezil produced statistically significant improvements in ADAS-cog, CIBIC plus, and Mini-Mental State Examination scores, relative to placebo, and there was a statistically significant positive correlation between plasma concentrations of donepezil and acetylcholinesterase inhibition; the EC50 was obtained at a concentration of 15.6 ng/mL.
Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease.
Huperzine-A in capsules and tablets for treating patients with Alzheimer disease.
  • S. Xu, Z. Cai, B. Feng
  • Medicine, Biology
    Zhongguo yao li xue bao = Acta pharmacologica Sinica
  • 1999
TLDR
There is equal efficacy and safety between Hup in capsule and tablet for treating patients with AD, and Hup can reduce the pathological changes of the oxygen free radicals in the plasma and erythrocytes of patients withAD.
Review on clinical application of huperzine A in China
TLDR
With the extension of clinic application, Huperzine A has been found to exert significant effect in the treatment of vascular dementia and cognitive deficits caused by other pathogenesis as well, indicating a prospering future in clinic application.
...
...